Navigation Links
EHA in Medical News

ASH and EHA Jointly Announce Translational Research Training in Hematology Program

BERLIN, June 5 /PRNewswire-USNewswire/ -- In an effort to foster global biomedical research that will ultimately lead to new and improved treatments for patients with blood diseases, the American Society of Hematology (ASH) and the European Hematology Association (EHA) have collaborated to create ...

ASH and EHA jointly announce translational research training in hematology program

(BERLIN, June 5, 2009) In an effort to foster global biomedical research that will ultimately lead to new and improved treatments for patients with blood diseases, the American Society of Hematology (ASH) and the European Hematology Association (EHA) have collaborated to create the Translational ...

Ireland's EHA Soft Solutions Selected to Supply Risk Management and Mitigation Software to Quality Employment Credentialing for Healthcare Workforce

CORK, Ireland and WASHINGTON, March 17 /PRNewswire/ --- EHA Soft Solutions (EHA), an Ireland-based provider of advanced software solutions to the healthcare, oil and gas, telecommunications and other industry segments, today announced that it has been selected by Quality Employment Credentialing (...

Third-Party Audits: EHA Consulting Group Releases Comments on Food Safety Consultant Auditors' Qualifications and Competencies

EHA Consulting Group ( http://www.ehagroup.com ), which has over 25 years of experience providing food safety consulting, released comments today about the qualifications and competencies of food safety auditors. (PRWEB) February 11, 2009 -- EHA Consulting Group ( http:...

Micromet, Inc. Reports Second Quarter 2009 Financial Results

... treated at lower doses (167 days versus 83 days). On June 8, The German Multicenter ALL Study Group (GMALL) presented data at the eha meeting in Berlin indicating that blinatumomab had achieved the primary endpoint in a phase 2 clinical trial in the treatment of ALL patients. The pr...

ChemGenex's omacetaxine may provide first viable treatment option for highly resistant form of CML

...mGenex's Chief Medical Officer Dr. Adam Craig will host an investor conference call and webcast to discuss the clinical results from both ASCO and the eha Congress on Thursday 11th of June at 10 am AEST. Details of this event will be advised in coming days. Omacetaxine Overview Omacetaxine mepesucc...

Public School Alliance Names Plan Advocate to Evaluate Services

...as direct questions to the appropriate party. eha selected Kurt Genrich as its Plan Advocate based o... boards. Genrich will lead a team that will enable eha to: Strengthen two-way communi...ual association conferences and provide updates at eha board and executive meetings Establish a q...

European blood researchers receive award to pursue research opportunities in US

...ce. The fellowship, which encourages increased collaboration between scientists, also grants recipients additional travel stipends to attend both the eha and ASH annual meetings. Dr. Alinari, of the Sragnoli Institute of Hematology and Medical Oncology in Italy, will pursue his research project, Ro...

More>>

EHA in Medical Technology

TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin

SAN DIEGO, May 14 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009. (Logo: http://www.newscom....

Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting

NEW HAVEN, Conn., June 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with acute myelogenous leukemia (AML) and high-risk m...

Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress

SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) will present data from ongoing clinical trials of voreloxin (formerly SNS-595) at two major upcoming oncology conferences. Updated interim data from Sunesis' ongoing Phase 2 clinical ...

Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting

NEW HAVEN, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. announced that it presented clinical data in a poster session at the 12th Congress of the European Hematology Association (EHA) Meeting in Vienna, Austria on its lead anticancer agent Cloretazine(R) (VNP40101M) as...

Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA

OSLO, Norway, 11 June 2007 - Clavis Pharma (OSE: CLAVIS) presented an update of data from its ongoing clinical Phase I/II study with ELACYT in hematologic cancers during a poster session at the Annual Meeting of the European Hematology Association (EHA) in Vienna. ELACYT is a novel cytotoxic agent...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...sease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing Phase II study. 14th Congress of the eha 2009, abstract no. 482 Webcast/Conference Call Micromet will host a webcast/conference call this morning from 9:00 am to 11:00 am U.S...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

...onse on initial treatment, demonstrating an important unmet need(6). eha study details The proof-of-concept, open-label, single-arm, multicen...olimus in Relapsed Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD). eha 14th Congress. Berlin, Germany National Cancer Institute. Genera...

Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis

... these patients. The data were highlighted in an oral presentation to the eha Congress by Anita Hill, MB, ChB, Consultant Hematologist at Bradford Teachi...se, which include disabling fatigue," said Dr. Hill. "The data presented at eha help us to understand that fatigue in PNH is tied much more closely to hemo...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

...mias later this year. SGI-1776 may become the first drug in this class of inhibitors to enter the clinic." SuperGen's schedule of presentations at eha is as follows: Date Time (PDT) Abstract # and Title Friday, June 13 8:45 a.m.-10 a.m. #744 - A potent small ...

Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study

...ny focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that data presented at the 12th Congress of eha in Vienna, Austria, showed positive responses in patients with non-Hodgkin's lymphoma (NHL) treated with a new radioimmunotherapy (RAIT) using epratuz...
EHA in Biological Technology

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

BETHESDA, Md., June 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a webcast on June 8, 2009 to discuss the blina...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

Activity of Blinatumomab in NHL and ALL Highlighted at the 14th Congress of the European Hematology Association (EHA) Adecatumumab Combination Data in Breast Cancer to Be Presented at the American Society of Clinical Oncology (ASCO) Meeting BETHESDA, Md., May 20 /PRNewswire-FirstCall/ --...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...imal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing Phase II study. 14th Congress of the eha 2009, abstract no. 482 About Micromet, Inc. Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for...

Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress

...d molar ratio cytarabine-daunorubicin for patients with advanced leukemia. eha Abstract #1398. Harasym T, Lim W, Tardi P, et al. Leukemia cell-se...un) mediated by CPX-351 liposome injection in the bone marrow compartment. eha Abstract #383 ...
Other Tags
(Date:8/20/2014)... August 20, 2014 A new trend ... a medical exam before issuing an approximate quote for ... company is now helping the public to obtain life ... system at http://quotespros.com/life-insurance.html . , The coverage ... more regulations have appeared in many U.S. states. Some ...
(Date:8/20/2014)... -- A group representing U.S. obstetricians is calling for ... According to the American College of Obstetricians and Gynecologists ... the safety and effectiveness of flu vaccination during pregnancy. ... be particularly dangerous to pregnant women, as it can ... Riley, chair of the college,s Immunization Expert Work Group, ...
(Date:8/20/2014)... study in Australia examined patient and tumor characteristics ... of tumor cell growth) in an effort to ... patients. , Author: Sarah Shen, ... and colleagues. , Background: The tumor characteristic ... has been connected with prognosis and survival in ...
(Date:8/20/2014)... Aug. 20, 2014 -- An imaging study of ... found deficits in specific regions of brain white ... in CCS users. , Researchers used diffusuion ... with fractional anisotropy, to investigate the white matter ... in multiple regions of the brain, including the ...
(Date:8/20/2014)... 20, 2014 (HealthDay News) -- Pigs, hearts transplanted into ... twice as long as previously achieved, researchers report. ... to use animal organs to shorten transplant waiting lists. ... engineered piglets into baboons, abdomens. The genetic engineering and ... are what enabled the hearts to survive for more ...
Breaking Medicine News(10 mins):Health News:Life Insurance Quotes Without Medical Exams Now Displayed to Adults at Insurance Website 2Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2
(Date:8/20/2014)... salty aroma of sunscreen and seawater signals a relaxing ... that the idyllic beach vacation comes with an environmental ... into the sea, they can become toxic to some ... course for many other marine animals. Their study appears ... . , Antonio Tovar-Sanchez and David Snchez-Quiles point out ...
(Date:8/20/2014)... A new gene therapy developed by researchers at the ... to protect mice from a life-threatening heart condition caused ... therapeutic avenue," said Yi Lai, Ph.D., the leading author ... MU School of Medicine,s Department of Molecular Microbiology and ... hope this could lead to a treatment for people ...
(Date:8/20/2014)... , Aug. 20, 2014  The second annual ... in Tampa, Florida on ... with Steven Rahman, Director, Technology and Strategy at Samsung, ... Experian. The theme of this year,s event is ... "Biometrics UnPlugged: Mobility at the ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
Other Contents